Table 4.
Comparison of clinical characteristics between the MPR group and the non-MPR group
| Non-MPR | MPR | P | |
|---|---|---|---|
| Patients | 16 (44.4%) | 20 (55.6%) | |
| Age | 66.5 (62.0–68.0) | 60.5 (54.5–67.8) | 0.147 |
| Sex | |||
| Male | 12 (75.0%) | 16 (80.0%) | |
| Female | 4 (25.0%) | 4 (20.0%) | 1.000 |
| Smoking history | |||
| No | 6 (37.5%) | 6 (30.0%) | |
| Yes | 10 (62.5%) | 14 (70.0%) | 0.729 |
| Treatment cycles | |||
| 2 | 8 (50.0%) | 10 (50.0%) | |
| 3 | 6 (37.5%) | 4 (20.0%) | |
| 4 | 2 (12.5%) | 6 (30.0%) | 0.321 |
| Adverse effect | |||
| No | 0 | 2 (10.0%) | |
| Grades 1–2 | 13 (81.2%) | 12 (60.0%) | |
| Grades 3–5 | 3 (18.8%) | 6 (30.0%) | 0.184 |
| Pre-treatment PD-L1 expression | |||
| Negative | 6 (37.5%) | 2 (10.0%) | |
| Positive | 2 (12.5%) | 8 (40.0%) | |
| Unknown | 8 (50.0%) | 6 (30.0%) | 0.054 |
| Pathology | |||
| Squamous cell carcinoma | 8 (50.0%) | 11 (55.0%) | |
| Adenocarcinoma | 5 (31.3%) | 4 (20.0%) | |
| Non-small-cell lung cancer | 3 (18.8%) | 5 (25.0%) | 0.724 |
| Clinical stage | |||
| IIB | 1 (6.3%) | 3 (15.0%) | |
| IIIA | 13 (81.2%) | 7 (35.0%) | |
| IIIB | 2 (12.5%) | 7 (35.0%) | |
| IIIC | 0 | 3 (15.0%) | 0.023 |
| Radiological response | |||
| CR | 0 | 8 (40.0%) | |
| PR | 12 (75.0%) | 12 (60.0%) | |
| SD | 4 (25.0%) | 0 | <0.001 |
MPR major pathologic response, CR complete response, PR partial response, SD stable disease, PD-L1 programmed cell death ligand 1